• 1
    Wood P, Stanworth S, Burton J et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007; 149:41023.
  • 2
    Liese JG, Wintergerst U, Tympner KD et al. High- vs. low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992; 146:3359.
  • 3
    Roifman CM, Lederman HM, Lavi S et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med 1985; 79:1714.
  • 4
    Cunningham-Rundles C, Siegal FP, Smithwick EM et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984; 101:4359.
  • 5
    Chapman SA, Gilkerson KL, Davin TD et al. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with d-sorbitol-stabilzed, formulation. Ann Pharmacother 2004; 38:205967.
  • 6
    US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency. Draft guidance November 2005 (finalized June 2008).
  • 7
    Committee for Proprietary Medicinal Products. Note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIG). London: 29 June 2000, CPMP/BPWG/388.95 rev. 1.
  • 8
    Berger M. A history of immune globulin therapy, from the Harvard Crash Program to monoclonal antibodies. Curr Allergy Asthma Rep 2002; 2:36878.
  • 9
    Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987; 1:10757.
  • 10
    Eijkhout HW, Van Der Meer JWM, Kallenberg GCM et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized double-blind, multicenter crossover trial. Ann Intern Med 2001; 135:16574.
  • 11
    Ochs HD, Morell A, Skvaril F et al. Survival of IgG subclasses following administration of intravenous gammaglobulin in patients with primary immunodeficiency diseases. In: MorellA, NydeggerUE, eds. Clinical use of intravenous immunoglobulins. London: Academic Press Inc., 1986:7785.
  • 12
    Church JA, Leibl H, Stein MR et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IVIG 10%] in patients with primary immunodeficiency. J Clin Immunol 2006; 26:38895.
  • 13
    Stein MR, Nelson RP, Church JA et al. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol 2009; 29:13744.
  • 14
    Berger M, Pinciaro PJ, Flebogamma® 5% Investigators. Safety, efficacy and pharmacokinetics of Flebogamma® 5% [Immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 2004; 24:38996.
  • 15
    Ochs HD, Pinciaro PJ, Octagam Study Group. Octagam® 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004; 24:30914.
  • 16
    Alyanakian MA, Bernatowska E, Scherrmann JM et al. Pharmacokinetics of total immunoglobulin and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency disorders. Vox Sang 2003; 84:18892.
  • 17
    Ballow M, Berger M, Bonilla FA et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%). Vox Sang 2003; 84:20210.
  • 18
    Dalakas MC, Clark WM. Strokes, thromboembolic events and IVIg. Rare incidents blemish an excellent safety record. Neurology 2003; 60:173637.